EP 1355649 A2 20031029 - PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES

Title (en)

PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES

Title (de)

PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND PYRAZOLO 4,3-D PYRIMIDINE UND NITRATE ODER THIENOPYRIMIDINE UND NITRATE

Title (fr)

FORMULATION PHARMACEUTIQUE CONTENANT DES PYRAZOLO 4,3-D PYRIMIDINES ET DES NITRATES OU DES THIENOPYRIMIDINES ET DES NITRATES

Publication

EP 1355649 A2 20031029 (DE)

Application

EP 01988079 A 20011227

Priority

DE 10104095 A 20010131
DE 10104096 A 20010131
DE 10104097 A 20010131
EP 0115324 W 20011227

Abstract (en)

[origin: US2004077664A1] Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.

IPC 1-7

A61K 31/505; A61P 9/00

IPC 8 full level

A61K 31/21 (2006.01); A61K 31/505 (2006.01); C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 11/02 (2006.01); A61P 11/06 (2006.01); A61P 13/12 (2006.01); A61P 15/10 (2006.01); A61P 27/06 (2006.01); A61P 35/00 (2006.01); A61P 37/08 (2006.01); C07D 495/04 (2006.01)

CPC (source: EP KR US)

A61K 31/505 (2013.01 - EP US); A61K 31/519 (2013.01 - EP KR US); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/04 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/02 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 15/10 (2018.01 - EP); A61P 27/06 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 39/00 (2018.01 - EP)

C-Set (source: EP US)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

US 2004077664 A1 20040422; AR 035741 A1 20040707; BR 0116849 A 20040225; CA 2436209 A1 20020808; CN 1499969 A 20040526; CZ 20032339 A3 20040915; EP 1355649 A2 20031029; HU P0302987 A2 20031229; JP 2004517940 A 20040617; KR 20030070149 A 20030827; MX PA03006717 A 20031024; PL 362408 A1 20041102; SK 10762003 A3 20040108; WO 02060449 A2 20020808; WO 02060449 A3 20030130

DOCDB simple family (application)

US 47048503 A 20030730; AR P020100323 A 20020130; BR 0116849 A 20011227; CA 2436209 A 20011227; CN 01822438 A 20011227; CZ 20032339 A 20011227; EP 0115324 W 20011227; EP 01988079 A 20011227; HU P0302987 A 20011227; JP 2002560641 A 20011227; KR 20037010043 A 20030730; MX PA03006717 A 20011227; PL 36240801 A 20011227; SK 10762003 A 20011227